These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28872919)
1. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Kalin A; Medina-Paraiso E; Ishizaki K; Kim A; Zhang Y; Saita T; Wasaki M Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):71-79. PubMed ID: 28872919 [TBL] [Abstract][Full Text] [Related]
2. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920 [TBL] [Abstract][Full Text] [Related]
3. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ; Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181 [TBL] [Abstract][Full Text] [Related]
5. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915 [TBL] [Abstract][Full Text] [Related]
6. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913 [TBL] [Abstract][Full Text] [Related]
7. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Takahashi F; Takei K; Tsuda K; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914 [TBL] [Abstract][Full Text] [Related]
8. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H; Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015 [TBL] [Abstract][Full Text] [Related]
9. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Takei K; Tsuda K; Takahashi F; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916 [TBL] [Abstract][Full Text] [Related]
10. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Bhandari R; Kuhad A; Kuhad A Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226 [TBL] [Abstract][Full Text] [Related]
11. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. EDARAVONE (MCI-186) ALS 16 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917 [TBL] [Abstract][Full Text] [Related]
12. Edaravone and its clinical development for amyotrophic lateral sclerosis. Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907 [TBL] [Abstract][Full Text] [Related]
13. Edaravone (Radicava) for ALS. Med Lett Drugs Ther; 2017 Nov; 59(1533):180-182. PubMed ID: 29125592 [No Abstract] [Full Text] [Related]
14. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Yoshino H; Kimura A Amyotroph Lateral Scler; 2006 Dec; 7(4):241-5. PubMed ID: 17127563 [TBL] [Abstract][Full Text] [Related]
15. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Park JM; Kim SY; Park D; Park JS Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Sawada H Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335 [TBL] [Abstract][Full Text] [Related]
17. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Edaravone Acute Infarction Study Group Cerebrovasc Dis; 2003; 15(3):222-9. PubMed ID: 12715790 [TBL] [Abstract][Full Text] [Related]
18. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Genge A; Pattee GL; Sobue G; Aoki M; Yoshino H; Couratier P; Lunetta C; Petri S; Selness D; Bidani S; Hirai M; Sakata T; Salah A; Apple S; Wamil A; Kalin A; Jackson CE Muscle Nerve; 2023 Feb; 67(2):124-129. PubMed ID: 36504406 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]